Lactate in the Gut
Primary Purpose
Lactate, Healthy, Hyperlactatemia
Status
Completed
Phase
Not Applicable
Locations
Denmark
Study Type
Interventional
Intervention
Oral Sodium Lactate
Intravenous sodium lactate
Sponsored by
About this trial
This is an interventional other trial for Lactate focused on measuring lactate, metabolism, Gastric emptying, GDF-15, insulin, incretin hormones
Eligibility Criteria
Inclusion Criteria:
- Male gender
- Age 18-50 years
- BMI 20-30 kg/m2
- In good health with no daily use of prescription medicine based on medical history, clinical examination and blood samples.
- Spoken and written informed consent
Exclusion Criteria:
- Chronic illness or daily use of prescription medicine .
- Abnormal screening blood samples as judged by the PI
- Does not understand or speak Danish
Sites / Locations
- Aarhus University Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
Oral lactate
Iso-lactic intravenous lactate infusion
Arm Description
Sodium D/L lactate solution, 25g/L in 300mL water
iv sodium D/L lactate to elevate [lactate] to the same levels as measured on day 1 + oral sodium chloride, 300 mL
Outcomes
Primary Outcome Measures
GDF-15
Difference in [GDF-15] between intervention and placebo
Secondary Outcome Measures
glucagon-like peptide -1
Difference in [glucagon-like peptide -1] between intervention and placebo
Gastric inhibitory peptide (GIP)
Difference in plasma [GIP] between intervention and placebo
free fatty acid
Difference in [free fatty acid ] between intervention and placebo
cholecystokinin
Difference in [cholecystokinin] between intervention and placebo
Ghrelin
Difference in [Ghrelin] between intervention and placebo
Gastrin
Difference in [Gastrin] between intervention and placebo
C-peptide
Difference in [C-peptide] between intervention and placebo
glucose
Difference in [glucose] between intervention and placebo
gastric emptying
[Paracetamol] to asses gastric emptying
Evaluation of hunger
Evaluation of hunger, thoughts of future food intake ect using a questionnaire
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04299815
Brief Title
Lactate in the Gut
Official Title
Lactate in the Gut
Study Type
Interventional
2. Study Status
Record Verification Date
February 2020
Overall Recruitment Status
Completed
Study Start Date
April 1, 2020 (Actual)
Primary Completion Date
July 29, 2020 (Actual)
Study Completion Date
July 29, 2020 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Aarhus
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Lactate is formed naturally in the body in example during physical activity. However, lactate is also formed during food fermentation where certain bacterial strains form lactate. Lactate can also be produced chemically. An example of this is Ringer-lactate which is used for volume replacement when treating dehydrated patients.
As a source of carbon-molecules, lactate is believed to be an important oxidative fuel source in all major organs and yields adenosine triphosphate (ATP) production through Krebs cycle, the Electron Transport Chain in the mitochondria as well as by being a key precursor for gluconeogenesis.
Metformin is the first drug of choice for type 2 diabetes treatment. Use of metformin often results in a small but significant weight loss in overweight users. It is known that metformin increases the lactate concentration in the gut. It is also known also know that metformin use is associated with an increase in blood concentrations of growth differentiation factor 15 (GDF-15). Receptors for GDF-15 can be found in parts of the brain associated with control of appetite. In rats increases in [GDF-15] results in a decrease in appetite and thus weight loss. GDF-15 is thought to be involved in the normal energy homeostasis.
With this study the investigators want to examine the hormonal, metabolic and mechanical effects of lactate in the gut in healthy volunteers. Our hypothesis is that lactate has beneficial effects which may be though an increase in GDF-15 in the blood.
Volunteers will undergo two study days separated by at least 7 days and a maximum of 1 month.
On day one volunteers will drink a sodium-lactate solution (intervention). The investigators will also administrate 1500mg paracetamol to assess gastric emptying and do blood samples over 4 hours. The investigators measure [lactate] every 15 min. Every hour the investigators will ask volunteers questions regarding hunger and thoughts of future food intake (questionnaire). After 4 hours of blood sampling the investigators will serve volunteers an all-you-can-eat meal of sandwich and measure how must they ate.
On day two volunteers will drink a sodium chloride solution. Furthermore, the investigators administrate intravenous D/L sodium lactate in order to reach the same plasma [lactate] on day 2 as was done on day 1. The rest of day two is identical to day 1.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Lactate, Healthy, Hyperlactatemia
Keywords
lactate, metabolism, Gastric emptying, GDF-15, insulin, incretin hormones
7. Study Design
Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
10 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Oral lactate
Arm Type
Active Comparator
Arm Description
Sodium D/L lactate solution, 25g/L in 300mL water
Arm Title
Iso-lactic intravenous lactate infusion
Arm Type
Placebo Comparator
Arm Description
iv sodium D/L lactate to elevate [lactate] to the same levels as measured on day 1 + oral sodium chloride, 300 mL
Intervention Type
Drug
Intervention Name(s)
Oral Sodium Lactate
Intervention Description
25 grams of D/L lactate dissolved in 300mL water.
Intervention Type
Drug
Intervention Name(s)
Intravenous sodium lactate
Intervention Description
intravenous sodium lactate + oral sodium-chlorid solution
Primary Outcome Measure Information:
Title
GDF-15
Description
Difference in [GDF-15] between intervention and placebo
Time Frame
4 hours
Secondary Outcome Measure Information:
Title
glucagon-like peptide -1
Description
Difference in [glucagon-like peptide -1] between intervention and placebo
Time Frame
4 hours
Title
Gastric inhibitory peptide (GIP)
Description
Difference in plasma [GIP] between intervention and placebo
Time Frame
4 hours
Title
free fatty acid
Description
Difference in [free fatty acid ] between intervention and placebo
Time Frame
4 hours
Title
cholecystokinin
Description
Difference in [cholecystokinin] between intervention and placebo
Time Frame
4 hours
Title
Ghrelin
Description
Difference in [Ghrelin] between intervention and placebo
Time Frame
4 hours
Title
Gastrin
Description
Difference in [Gastrin] between intervention and placebo
Time Frame
4 hours
Title
C-peptide
Description
Difference in [C-peptide] between intervention and placebo
Time Frame
4 hours
Title
glucose
Description
Difference in [glucose] between intervention and placebo
Time Frame
4 hours
Title
gastric emptying
Description
[Paracetamol] to asses gastric emptying
Time Frame
4 hours
Title
Evaluation of hunger
Description
Evaluation of hunger, thoughts of future food intake ect using a questionnaire
Time Frame
4 hours
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Male gender
Age 18-50 years
BMI 20-30 kg/m2
In good health with no daily use of prescription medicine based on medical history, clinical examination and blood samples.
Spoken and written informed consent
Exclusion Criteria:
Chronic illness or daily use of prescription medicine .
Abnormal screening blood samples as judged by the PI
Does not understand or speak Danish
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Nikolaj Rittig, postdoc
Organizational Affiliation
Steno Diabetes Center Aarhus (SDCA), Aarhus universitetshospital
Official's Role
Study Chair
Facility Information:
Facility Name
Aarhus University Hospital
City
Aarhus
ZIP/Postal Code
8200
Country
Denmark
12. IPD Sharing Statement
Citations:
PubMed Identifier
35016146
Citation
Pedersen MGB, Sondergaard E, Nielsen CB, Johannsen M, Gormsen LC, Moller N, Jessen N, Rittig N. Oral lactate slows gastric emptying and suppresses appetite in young males. Clin Nutr. 2022 Feb;41(2):517-525. doi: 10.1016/j.clnu.2021.12.032. Epub 2021 Dec 24.
Results Reference
derived
Learn more about this trial
Lactate in the Gut
We'll reach out to this number within 24 hrs